Oraya Therapeutics Achieves Successful INTREPID Study Outcomes with a Non-Invasive Radiation Therapy for Wet AMD
5/3/2012 10:34:01 AM
NEWARK, Calif.--(BUSINESS WIRE)--Oraya Therapeutics, Inc. today announced that the INTREPID clinical trial of radiation therapy has met its primary endpoint of reduction in anti-VEGF injections for patients with wet age-related macular degeneration (wet AMD). The INTREPID study is the first sham-controlled double-masked trial to evaluate the effectiveness and safety of a one-time radiation therapy in conjunction with as-needed anti-VEGF injections for the treatment of wet AMD. Preliminary result analyses found no indication of radiation-related adverse events at the one-year trial end point. The results from the INTREPID study will be presented during the EURETINA Congress in Milan, Italy (September 6-9, 2012).